CATH Search:   
       by CATH code, keyword
QuickSearch:   
by PDB,NDB,UniProt,PROSITE Code or Search Term(s)  
(use 'Shift Left-Click' to collapse/expand all levels downwards; use 'Control Left-Click' to collapse/expand all levels upwards)
 
(-)
Class: Mainly Alpha (13335)
(-)
Architecture: Orthogonal Bundle (10391)
(-)
Topology: Cyclin A; domain 1 (136)
(-)
Homologous Superfamily: [code=1.10.472.10, no name defined] (99)
(-)
Human (Homo sapiens) (84)
1AD6A:378-562DOMAIN A OF HUMAN RETINOBLASTOMA TUMOR SUPPRESSOR
1E9HB:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
1F5QB:6-36,B:146-252; D:6-36,D:146-252; B:37-145; D:37-145CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
1FINB:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
1FVVB:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
1G3NC:16-34,C:148-253; G:16-34,G:148-252; C:35-147; G:35-147STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
1GUXB:645-785; A:380-577RB POCKET BOUND TO E7 LXCXE MOTIF
1H1PB:181-194,B:308-432; D:181-194,D:308-432; B:195-307; D:195-307STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
1H1QB:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
1H1RB:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
1H1SB:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
1H24B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
1H25B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
1H26B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
1H27B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
1H28B:181-194,B:308-432; D:181-194,D:308-432; B:195-307; D:195-307CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
1H4LD:147-293; E:147-293STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
1JKWA:161-261; A:11-160,A:262-287STRUCTURE OF CYCLIN MCS2
1JSTB:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
1JSUB:181-194,B:308-432; B:195-307P27(KIP1)/CYCLIN A/CDK2 COMPLEX
1KXUA:161-261; A:11-160,A:262-286CYCLIN H, A POSITIVE REGULATORY SUBUNIT OF CDK ACTIVATING KINASE
1N4MA:564-785; B:564-785; B:380-563; A:380-563STRUCTURE OF RB TUMOR SUPPRESSOR BOUND TO THE TRANSACTIVATION DOMAIN OF E2F-2
1O9KB:644-787; D:644-787; F:644-787; H:644-787; A:379-578; C:379-578; E:379-578; G:379-578CRYSTAL STRUCTURE OF THE RETINOBLASTOMA TUMOUR SUPPRESSOR PROTEIN BOUND TO E2F PEPTIDE
1OGUB:181-194,B:308-431; D:195-307; B:195-307; D:181-194,D:308-432STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
1OI9D:181-194,D:308-430; B:195-307; D:195-307; B:181-194,B:308-432STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
1OIUB:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
1OIYB:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
1OKVB:181-194,B:308-431; B:195-307; D:195-307; D:181-194,D:308-432CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
1OKWB:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
1OL1B:181-194,B:308-432; D:181-194,D:308-432; B:195-307; D:195-307CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
1OL2B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
1P5EB:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4,5,6,7-TETRABROMOBENZOTRIAZOLE (TBS)
1PKDB:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN A
1QMZB:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
1TFBA:208-316; A:113-207NMR STUDIES OF HUMAN GENERAL TRANSCRIPTION FACTOR TFIIB: DYNAMICS AND INTERACTION WITH VP16 ACTIVATION DOMAIN, 20 STRUCTURES
1UNGE:147-294; D:145-294STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE, ALOISINE AND INDIRUBIN.
1UNHD:147-294; E:147-294STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE, ALOISINE AND INDIRUBIN.
1UNLD:145-294; E:145-294STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE, ALOISINE AND INDIRUBIN.
1URCB:181-194,B:308-431; B:195-307; D:195-307; D:181-194,D:308-432CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
1VYWB:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
1W98B:114-227; B:97-113,B:228-357THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E
2B9RA:23-134; B:23-134CRYSTAL STRUCTURE OF HUMAN CYCLIN B1
2BKZB:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
2BPMB:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
2C4GB:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
2C5NB:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2C5OB:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2C5VB:181-194,B:308-432; D:181-194,D:308-432; B:195-307; D:195-307DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2C5XB:181-194,B:308-432; D:181-194,D:308-432; B:195-307; D:195-307DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2C6TB:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2CCHD:181-194,D:308-431; B:181-194,B:308-432; B:195-307; D:195-307THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA-LINKED ATP ANALOGUE
2CCIB:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
2CJMB:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
2G9XB:181-194,B:308-432; D:181-194,D:308-432; B:195-307; D:195-307STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
2I40B:181-194,B:308-431; D:181-194,D:308-432; B:195-307; D:195-307CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
2IW6B:181-194,B:308-431; B:195-307; D:195-307; D:181-194,D:308-431STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2IW8B:181-194,B:308-431; D:195-307; B:195-307; D:181-194,D:308-431STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V-H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
2IW9B:181-194,B:308-431; D:195-307; B:195-307; D:181-194,D:308-431STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2JGZB:187-298CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B
2PHGA:208-316; A:113-207MODEL FOR VP16 BINDING TO TFIIB
2R7GA:564-785; C:564-785; A:380-563; C:380-563STRUCTURE OF THE RETINOBLASTOMA PROTEIN POCKET DOMAIN IN COMPLEX WITH ADENOVIRUS E1A CR1 DOMAIN
2UUEB:181-194,B:308-432; D:181-194,D:308-432; B:195-307; D:195-307REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
2UZBB:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2UZDB:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2UZEB:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2UZLB:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2V22B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
2WEVB:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2WFYB:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2WHBB:181-194,B:308-432; D:181-194,D:308-432; B:195-307; D:195-307TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2WIHD:181-194,D:308-432; B:195-307; D:195-307; B:181-194,B:308-432STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
2WIPB:181-194,B:308-432; D:181-194,D:308-432; B:195-307; D:195-307STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1-METHYL-4,5-DIHYDRO-1H-PYRAZOLO[4,3-H] QUINAZOLINE-3-CARBOXYLIC ACID
2WPAB:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432OPTIMISATION OF 6,6-DIMETHYL PYRROLO 3,4-C PYRAZOLES: IDENTIFICATION OF PHA-793887, A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
2WXVB:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(4,3-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
2X1NB:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
3BHTB:181-194,B:308-432; D:181-194,D:308-432; B:195-307; D:195-307STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
3BHUB:181-194,B:308-432; D:181-194,D:308-432; B:195-307; D:195-307STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
3BHVB:181-194,B:308-432; D:181-194,D:308-432; B:195-307; D:195-307STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
3DDPB:181-194,B:308-432; D:181-194,D:308-438; B:195-307; D:195-307STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
3DDQB:181-194,B:308-432; D:181-194,D:308-439; B:195-307; D:195-307STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
3DOGB:181-194,B:308-432; D:181-194,D:308-434; B:195-307; D:195-307STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
3EIDB:181-194,B:308-432; D:181-194,D:308-432; B:195-307; D:195-307CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
3EJ1B:181-194,B:308-432; D:181-194,D:308-432; B:195-307; D:195-307CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
3F5XB:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE